Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from the pivotal...
BMS
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Approved by EC for MSI-H/mCRC
Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that it has received marketing...
BioArctic AB Secures Global Rights to PyroGlu-Aβ Antibody Program in BMS Deal
Sweden-based BioArctic AB (OTCMKTS: BRCTF) has announced a significant licensing agreement with US pharmaceutical giant...
Fangzhou Inc. Partners with BMS to Innovate Digital Medicine Platform
China-based Internet healthcare solutions provider Fangzhou Inc. (HKG: 6086) has entered into a partnership with...
BMS Regains Exclusive Rights to ABZ-706 in Greater China
Bristol-Myers Squibb (BMS; NYSE: BMY) has reached an agreement with China-based Ablaze Pharmaceuticals to regain...
AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics
US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with...
Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
BMS’s Opdivo Secures NMPA Approval for Urothelial Carcinoma Treatment
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that it has received another indication approval...
Legend Biotech Corporation Appoints Alan Bash as President of Carvykti
China-based chimeric antigen receptor (CAR) T cell therapy specialist, Legend Biotech Corporation (NASDAQ: LEGN), has...
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...
BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...
BMS’s Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China
On October 14, 2024, Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the National Medical Products...
BeiGene Prices TEVIMBRA 10% Below Competitors Following FDA Approval for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the commercial availability of TEVIMBRA (Tislelizumab)...
BMS Expands Opdivo Indication with FDA Approval for NSCLC Combo Therapy
The U.S. Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS,...
FDA Panel Weighs in on Narrowing Use of PD-1 Inhibitors in Stomach and Esophageal Cancers
The U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) convened on September 26 to scrutinize the...
2seventy bio and BMS Discontinue Phase III Trial for Multiple Myeloma Therapy Abecma
2seventy bio Inc. (NASDAQ: TSVT), a U.S.-based biotechnology company partnered with Bristol-Myers Squibb (BMS, NYSE:...
Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first...
Qilu Pharmaceutical Gains Approval for Generic Dasatinib, Expanding CML Treatment Options in China
Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...